ICON plc (ICLR) Company Gross Revenue

ICON plc - graphic logo of issuer ICLR

Low geopolitical risks ensure operational stability for ICON Public (ICLR), as confirmed by the company's execution history: the parameter value is 8.23. This success is based on strategic alliances with industry behemoths and the implementation of remote testing to protect margins. Long-term contracts provide additional resilience, allowing the company to regularly exercise its pricing power.

iconplc.com (ICLR) Revenue and Sales Volume: for the period 07/04/2022 - 11/13/2026

Analytical breakdowns for ICON Public

- share price and consensus valuation forecast:
Price iconplc.com|ICLR - Price Target Chart
- market capitalization details:
Market Capitalization ICON plc|ICLR - Enterprise Value
- book capitalization data:
Net Assets per Share ICON|ICLR - Book Capitalization|Market Cap to Net Assets Ratio iconplc.com|ICLR - Aggregate Company Assets
- debt and solvency information:
Debt to Capital ICON Public|ICLR - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio ICON Public Limited Company|ICLR - Company Total Debt|Debt to Net Assets Ratio ICON plc|ICLR - Company Long-Term Debt|Current Liabilities ICON|Quick Ratio iconplc.com
- earnings and market multiples details:
ICLR - Net Profit|Expected Profit ICON Public|ICLR - Price to Earnings Ratio|Future Price to Earnings ICON Public|ICLR - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio ICON plc|ICLR - Operating profit EBITDA|Net earnings per share for the last 12 months ICON|ICLR - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months iconplc.com|ICLR - Earnings growth in current year|Expected earnings per share growth for next year ICON Public
- company sales and revenue statistics:
ICLR - Company Revenue|Company Projected Revenue ICON plc|ICLR - Price-to-Revenue Ratio|Forward Price to Sales ICON plc
General company analysis:ICON Corp - ICLR
Original product of ICON Corp

The scale of ICON Public (ICLR) business is determined by the daily cash inflow from the delivery of drug development services. This metric captures actual cash receipts, eliminating reporting time lags. By analyzing the company's absolute sales, an investor assesses current demand and the risk of asset overheating. This trend reflects the effectiveness of partnerships with pharma behemoths and data providers. The steady growth of the curve confirms the fundamental stability of the operating model.

Analysis of competing companies

IQV (Quintiles) - Company Total Sales|Company Revenue Labcorp Holdings Inc. (LH)|Company Gross Revenue medpace.com|Revenue and Sales Volume CRL (Charles River)|Company Gross Revenue Evotec AG (EVO)|Fortrea Corp - Revenue and Sales Volume|Lifecore Biomedical (LFCR) - Company Sales|OmniAb, Inc. (OABI) - Company Revenue|Company Total Revenue inotivco.com (NOTV)|Company Revenue Avid Bioservices|Company Sales Volume CTLT (Catalent Inc.)|Company Sales SCPX (NightHawk Biosciences)